Pramoda Challagundla

发表

Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome

M. Goswami, W. Decker, J. Jorgensen, 2014, Clinical Cancer Research.

Establishment and characterization of a novel MYC/BCL2 “double-hit” diffuse large B cell lymphoma cell line, RC

L. Medeiros, J. Jorgensen, L. Pham, 2015, Journal of Hematology & Oncology.

Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.

R. Kanagal-Shamanna, L. Medeiros, J. Jorgensen, 2014, Archives of pathology & laboratory medicine.

Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease

Michael L. Wang, Liang Zhang, J. Jorgensen, 2015, Leukemia & lymphoma.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

H. Kantarjian, F. Ravandi, S. Pierce, 2011, Blood.

Chemokine Receptor 4 Antibody , in Patients with Aggressive / Refractory Mycosis Fungoides and S ezary Syndrome

M. Goswami, W. Decker, J. Jorgensen, 2014 .

Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging.

R. Kanagal-Shamanna, L. Medeiros, J. Jorgensen, 2014, American journal of clinical pathology.

Utility of CD26 in flow cytometric immunophenotyping of T‐cell lymphomas in tissue and body fluid specimens

L. Medeiros, J. Jorgensen, Marian J. Kersh, 2008, Cytometry. Part B, Clinical cytometry.

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2013, Blood.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Z. Estrov, M. Keating, S. O'brien, 2014, Blood.

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

J. Jorgensen, M. Duvic, Youn H. Kim, 2015, Blood.

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

M. Goswami, J. Jorgensen, M. Duvic, 2012 .

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

E. Jabbour, U. Popat, Q. Bashir, 2013 .